Abstract
We evaluated the activity of ceftobiprole against 100 community-associated methicillin-resistant Staphylococcus aureus (CA-MRSA) and 100 hospital-associated MRSA (HA-MRSA) isolates. Eight isolates were evaluated by time-kill studies for kill rate and potential for synergy with tobramycin. Ceftobiprole MIC(50) and MIC(90) values were 1 and 2 microg/ml, respectively, against CA-MRSA and HA-MRSA. In time-kill analysis, ceftobiprole was bactericidal at all concentrations tested.
Publication types
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Acetamides / pharmacology*
-
Anti-Bacterial Agents / pharmacology
-
Cephalosporins / pharmacology*
-
Community-Acquired Infections / drug therapy
-
Community-Acquired Infections / microbiology
-
Cross Infection / drug therapy
-
Cross Infection / microbiology
-
Daptomycin / pharmacology*
-
Drug Synergism
-
Humans
-
Linezolid
-
Methicillin Resistance*
-
Microbial Sensitivity Tests
-
Oxazolidinones / pharmacology*
-
Staphylococcal Infections / drug therapy
-
Staphylococcal Infections / microbiology
-
Staphylococcus aureus / drug effects*
-
Vancomycin / pharmacology*
Substances
-
Acetamides
-
Anti-Bacterial Agents
-
Cephalosporins
-
Oxazolidinones
-
ceftobiprole
-
Vancomycin
-
Linezolid
-
Daptomycin